Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
L.A.G. Ries, M.A. Smith, J.G. Gurney, M. Linet, T. Tamra, J.L. Young, et al.
Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995,
[2.]
P. Kleihues, W.K. Cavenee.
Pathology and genetics of tumours of the nervous system, pp. 208-241
[3.]
I.F. Pollack, R.L. Hamilton, J. Burham, E.J. Holmes, S.D. Finkelstein, R. Sposto, et al.
Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
Neurosurgery, 50 (2002), pp. 1238-1244
[5.]
J.H. Wisoff, J.M. Boyett, M.S. Berger, C. Brant, H. Li, A.J. Yates, et al.
Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG–945.
J Neurosurg, 90 (1999), pp. 52-59
[6.]
C. Kalifa, D. Valteau, B. Pizer, G. Vassal, J. Grill, O. Hatrmann.
High dose chemotherapy in childhood brain tumours.
Child Nerv Syst, 15 (1999), pp. 498-505
[7.]
P.K. Duffner, J.P. Krischer, P.C. Burger, M.E. Cohen, J.W. Backstrom, M.E. Horowitz, et al.
Treatment of infants with malignant gliomas: the POG experience.
J Neurooncol, 28 (1996), pp. 245-256
[8.]
J.C. Nicholson, F.M. Ross, J.A. Kohler, D.W. Ellison.
Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours.
Br J Cancer, 80 (1999), pp. 1322-1331
[9.]
R.J. Packer, J. Goldwein, H.S. Nicholson, L.G. Vezina, J.C. Allen, M.D. Ris, et al.
Treatment of children with medulloblastoma with reduced dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Study Group.
J Clin Oncol, 17 (1999), pp. 2127-2136
[10.]
P.K. Duffner, M.E. Horowitz, J.P. Krischer, H.S. Friedman, P.C. Burger, M.E. Cohen, et al.
Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.
N Engl J Med, 328 (1993), pp. 1725-1731
[11.]
D.R. Copeland, C. DeMoor, I.I.I. Moore BD, J.L. Ater.
Neurocognitive development of children after a cerebellar tumor in infancy: a longitudinal study.
J Clin Oncol, 17 (1999), pp. 3476-3486
[12.]
R.I. Jakacki, P.M. Zeltzer, J.M. Boyett, A.L. Albright, J.C. Allen, J.R. Geyer, et al.
Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Childrens Cancer Group.
J Clin Oncol, 13 (1995), pp. 1377-1383
[13.]
A.T. Reddy, A.J. Janss, P.C. Phillips, H.L. Weiss, R.J. Packer.
Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy.
Cancer, 88 (2000), pp. 2189-2193
[14.]
D. Strother, D. Ashley, S.J. Kellie, A. Patel, D. Jones-Wallace, S. Thompson, et al.
Feasibility of four consecutive high-dose chemotherapy cycles with stem cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
J Clin Oncol, 15 (2001), pp. 2696-2704
[15.]
C.R. Freeman, J.P. Farmer.
Pediatric brain stem gliomas: a review.
Int J Radiation Oncol Biol Phys, 40 (1998), pp. 265-271
[16.]
C.R. Freeman, J. Kneper, L.E. Kun, R.A. Sandford, R. Kadota, L. Mandell, et al.
A detrimental effect of a combained chemotherapy- radiotherapy approach in children with diffuse intrinsic brain stem gliomas.
Int J radiation Oncol Biol Phys, 47 (2000), pp. 561-564
[17.]
H. Ikeda, T. Lehara, Y. Tsuchida, M. Kaneko, J. Hata, H. Naito, et al.
Experience with International Neuroblastoma Staging System and Pathology Classification.
Br J Cancer, 86 (2002), pp. 1110-1116
[18.]
S.J. Cotterill, A.D. Pearson, J. Pritchard, A.B. Foot, B. Roald, J.A. Kohler, et al.
Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group “Survey” 1982–1992.
Eur J Cancer, 36 (2000), pp. 901-908
[19.]
M.L. Schmidt, J.N. Lukens, R.C. Seeger, G.M. Brodeur, H. Shimada, R.B. Gerbing, et al.
Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study.
J Clin Oncol, 18 (2000), pp. 1260-1268
[20.]
C. Poremba, B. Hero, H.G. Goertz, C. Scheel, D. Wai, K.L. Schaefer, et al.
Traditional and emerging molecular markers in neuroblastoma prognosis: the good, the bad and the ugly.
Klin Padiatr, 213 (2001), pp. 186-190
[21.]
M. Lastowska, C. Cullinane, S. Variend, S. Cotterill, N. Bown, S. O'Neill, et al.
Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors.
J Clin Oncol, 19 (2001), pp. 3080-3090
[22.]
K.K. Matthay, J.G. Villablanca, R.C. Seeger, D.O. Stram, R.E. Harris, R.K. Ramsay, et al.
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
N Engl J Med, 341 (1999), pp. 1165-1173
[23.]
C. Mitchell, P.M. Jones, A. Kelsey, G.M. Vujanic, B. Marsden, R. Shannon, et al.
The treatment of Wilms' tumour: results of the United Kingdom Children's cancer study group (UKCCSG) second Wilms' tumour study.
Br J Cancer, 83 (2000), pp. 602-608
[24.]
L. Diller, M. Ghahremani, J. Morgan, P. Grundy, C. Reeves, N. Breslow, et al.
Constitutional WT1 mutations in Wilms' tumor patients.
J Clin Oncol, 16 (1998), pp. 3634-3640
[25.]
J.B. Beckwith.
Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations.
Am J Med Genet, 79 (1998), pp. 268-273
[26.]
G.M. Vujanic, D. Harms, B. Sandstedt, A. Weirich, J. De Kraker, J.F. Delemarre.
New definitions of focal and diffuse anaplasia in Wilms tumor: the International Society of Paediatric Oncology (SIOP) experience.
Med Pediatr Oncol, 32 (1999), pp. 317-323
[27.]
J.A. Meisel, K.A. Guthrie, N.E. Breslow, S.S. Donaldson, D.M. Green.
Significance and management of computed tomography detected pulmonary nodules: a report from the National Wilms Tumor Study Group.
Int J Radiat Oncol Biol Phys, 44 (1999), pp. 579-585
[28.]
D.M. Green, N.E. Breslow, J.B. Beckwith, J.Z. Finklestein, P.E. Grundy, P.R. Thomas, et al.
Comparison between singledose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
J Clin Oncol, 16 (1998), pp. 237-245
[29.]
D.M. Green, N.E. Breslow, J.B. Beckwith, J.Z. Finklestein, P.E. Grundy, P.R. Thomas, et al.
Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group.
J Clin Oncol, 16 (1998), pp. 3744-3751
[30.]
L. Diller, E. Sexsmith, A. Gottlieb, F.P. Li, D. Malkin.
Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.
J Clin Invest, 95 (1995), pp. 1606-1611
[31.]
J.G. Gurney, J.r. Young JL, S.D. Roffers, et al.
Soft tissue sarcomas.
Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, pp. 111-124
[32.]
D.M. Parham.
Pathologic classification of rhabdomyosarcomas and correlations with molecular studies.
Mod Pathol, 14 (2001), pp. 506-514
[33.]
P.H. Sorensen, J.C. Lynch, S.J. Qualman, R. Tirabosco, J.F. Lim, M.H. Maurer, et al.
PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
J Clin Oncol, 20 (2002), pp. 2672-2679
[34.]
R.B. Raney, J.R. Anderson, F.G. Barr, S.S. Donaldson, A.S. Pappo, S.J. Qualman, et al.
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
J Pediatr Hematol Oncol, 23 (2001), pp. 215-220
[35.]
J.r. Lawrence W, J.R. Anderson, E.A. Gehan, H. Maurer.
Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group.
Cancer, 80 (1997), pp. 1165-1170
[36.]
J.C. Breneman, E. Lyden, A.S. Pappo, M.P. Link, J.R. Anderson, D.M. Parham, et al.
Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma. a report from the Intergroup Rhabdomyosarcoma Study IV.
J Clin Oncol, 21 (2003), pp. 78-84
[37.]
W.M. Crist, J.R. Anderson, J.L. Meza, C. Fryer, R.B. Raney, F.B. Ruymann, et al.
Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
J Clin Oncol, 19 (2001), pp. 3091-3102
[38.]
M.P. Link, M.C. Gebhart, P.A. Meyers.
Osteosarcoma.
Principles and practice of pediatric oncology, 4th ed, pp. 1051-1089
[39.]
J.P. Ginsberg, S.Y. Woo, M.E. Johnson, M.E. Hicks, M.E. Horowitz.
Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors.
Principles and practice of pediatric oncology, 4th ed, pp. 973-1016
[40.]
M.D. Tabone, P. Terrier, H. Pacquement, M. Brunat, C. Smchmitt, A. Babin, et al.
Outcome of radiation-related osteosarcoma after treatment of childhood and adolescent cancer: a study of 23 cases.
J Clin Oncol, 17 (1999), pp. 2789-2795
[41.]
E. De Alava, A. Kawai, J.H. Healey, I. Fligman, P.A. Meyers, A.G. Huvos, et al.
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.
J Clin Oncol, 16 (1998), pp. 1248-1255
[42.]
S.S. Bielack, B. Kempf-Bielack, G. Delling, G.U. Exner, S. Flege, K. Helmke, et al.
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.
J Clin Oncol, 20 (2002), pp. 776-790
[43.]
H.E. Grier, M.D. Krailo, N.J. Tarbell, M.P. Link, C.J. Fryer, D.J. Pritchard, et al.
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
N Engl J Med, 348 (2003), pp. 694-701
[44.]
E.A. Kolb, B.H. Kushner, R. Gorlick, C. Laverdiere, J.H. Healey, M.P. LaQuaglia, et al.
Long-term event free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
J Clin Oncol, 21 (2003), pp. 3423-3430
[45.]
J.A. Ortega, E.C. Douglass, J.H. Feusner, M. Reynolds, J.J. Quinn, M.J. Finegolg, et al.
Randomized comparison of cisplatin/vincristine/ fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group.
J Clin Oncol, 18 (2000), pp. 2665-2675
[46.]
H.M. Katzenstein, M.D. Krailo, M.H. Malogolowkin, J.A. Ortega, W. Liu-Mares, E.C. Douglass, et al.
Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study.
J Clin Oncol, 20 (2002), pp. 2789-2797
[47.]
B. Cushing, E.J. Perlman, N.M. Marina, R.P. Castleberry.
Germ cell tumors.
Principles and practice of pediatric oncology, 4th ed, pp. 1091-1114
[48.]
C. Bokemeyer, C. Kollmannsberger, C. Meisner, A. Harstric, J. Beyer, B. Metzner, et al.
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis.
J Clin Oncol, 17 (1999), pp. 3450-3456
[49.]
S. Bhatia, R. Abonour, P. Porcu, R. Seshadri, C.R. Nichols, K. Cornetta, et al.
High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer.
J Clin Oncol, 18 (2000), pp. 3346-3351
[50.]
R.J. Motzer, M. Mazumdar, J. Sheinfeld, D.F. Bajorin, H.A. Macapinlac, M. Bains, et al.
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.
J Clin Oncol, 18 (2000), pp. 1173-1180
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados